What Optifen Dolo Treats: Main Uses and Benefits

The medicine provides symptomatic assistance where both pain relief and a reduction of inflammatory or irritative states are needed. This formulation is commonly used across conditions presenting with acute episodes where symptoms related to physical discomfort are prominent.

The medicine is used for managing symptom clusters that may become intense or disruptive, particularly in contexts where additional management of discomfort is required for mild to moderate acute pain. This is commonly used in clinical settings that involve acute or unstable symptom patterns.

The medicine may assist with situations involving certain distressing symptoms related to physical discomfort, such as those that interfere with daily functioning, including headache, backache, muscular and rheumatic pain, dental pain, period pain (dysmenorrhea), and fever and cold and flu symptoms. This treatment supports patients during episodes of heightened discomfort by easing the overall symptom burden.

“This supportive relief helps patients cope more steadily during difficult episodes by easing distress.”

This approach contributes to maintaining functional stability when supportive symptom management is appropriate.

---

Quick Fact: Relief for Symptoms that interfere with daily functioning

Regulatory References

1. GOV.UK Patient Information Leaflet

The eligibility for using Optifen Dolo (Ibuprofen) is strictly defined by regulatory authorities based on age, health history, and specific physiological states.

Contraindicated Populations (Must Not Use)
Known hypersensitivity to Ibuprofen, aspirin, or other NSAIDs.
Active or a history of recurrent peptic ulcer or gastrointestinal bleeding.
Severe organ failure (heart, renal, or hepatic) [1.1].
In the setting of Coronary Artery Bypass Graft (CABG) surgery [1.2].

Conditional/Restricted Eligibility
Pregnancy: Avoid use from 20 weeks gestation onward; contraindicated in the third trimester (30 weeks onward) [1.7].
Pediatric: Generally not recommended for children under 6 months of age [3.2].
Elderly Patients: Use requires caution due to officially documented increased risk of gastrointestinal and cardiovascular events [1.2].
Mild-to-Moderate Impairment: Use requires caution in mild-to-moderate renal or hepatic impairment and in uncontrolled hypertension [1.1, 2.7].

Eligibility for use is permitted in adults and adolescents without these documented conditions, including children ge 6 months of age. These regulations reflect the standardized classifications used in official prescribing information to manage risk associated with NSAID use.

The official interaction profile for Optifen Dolo, defined by government regulatory labeling, establishes specific restrictions and documented co-administration risks. Formal prohibitions exist against co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including cyclooxygenase-2 selective inhibitors. The medicine is also strictly contraindicated for use in the perioperative setting of Coronary Artery Bypass Graft (CABG) surgery.

Interactions involving anticoagulants (e.g., Warfarin), oral corticosteroids, and Selective Serotonin Reuptake Inhibitors (SSRIs) are documented as significantly increasing the risk of serious gastrointestinal bleeding. A pharmacodynamic antagonism is cited when co-administered with antihypertensives and diuretics, which may diminish the therapeutic effectiveness of those medicines.

Ibuprofen interferes with the elimination of certain drugs, resulting in a documented risk of increased plasma concentration for both Lithium and Methotrexate due to reduced renal clearance. A specific timing rule is mandated for immediate-release low-dose Acetylsalicylic acid (Aspirin): Ibuprofen must be administered at least 8 hours before or 30 minutes after the Aspirin dose to prevent interference with its anti-platelet effect.

Furthermore, the label notes a heightened risk of renal function deterioration when combined with ACE inhibitors or ARBs in elderly or volume-depleted patients.

Optifen Dolo, containing the active substance ibuprofen, functions as a non-selective, reversible inhibitor of the cyclooxygenase (COX) enzymes, specifically COX-1 (PTGS1) and COX-2 (PTGS2). The drug molecule interacts with and blocks the active sites of both isoenzymes, impeding their catalytic function. These enzymes are responsible for the conversion of arachidonic acid, released from cell membrane phospholipids, into prostaglandin G2 (PGG2) and subsequently prostaglandin H2 (PGH2).

By inhibiting COX activity, the drug significantly downregulates the entire molecular and intracellular pathway of eicosanoid synthesis. This reduction in PGH2 consequently leads to decreased synthesis and release of downstream prostanoid lipid mediators, including prostaglandin E2 (PGE2) and prostacyclin (PGI2), which act on various G-protein coupled receptors. The system-level physiological consequence of this generalized prostanoid synthesis modulation is the dampening of localized vascular dilation and the reduction of afferent neuron sensitization.

How to Use Optifen Dolo: Official Administration Guidelines

Optifen Dolo, which is an oral formulation of Ibuprofen, must be used in accordance with the instructions provided in the product information. The general principle for its use is to administer the lowest effective dose for the shortest duration necessary to manage symptoms.

---

Dosing and Frequency

The medicine is for oral use only. The standard single dose for adults and adolescents (ge 12 years) is 400 mg (one soft capsule).

• Single Dose Maximum: 400 mg Ibuprofen.
• Maximum Daily Dose: 1200 mg in any 24-hour period, which limits intake to no more than three doses daily.
• Dosing Interval: A minimum interval of at least 4 hours must be observed between doses.

Administration Requirements

The soft capsule must be swallowed whole with a glass of water. It is explicitly instructed that the capsule should not be chewed, crushed, or sucked, as this violates the intended administration route for the soft capsule formulation. The medicine may be taken with or after food as a usage consideration, although this may delay the onset of the drug's action.

Duration of Use and Specific Groups

The product is intended for short-term use only. Adults must seek consultation if the product is required for more than 4 days for pain or 3 days for fever. The standard adult dosing regimen applies to adolescents (ge 12 years). For patients with mild or moderate renal or hepatic impairment, no special dose reduction is required for this short-term use, but patients should adhere strictly to the minimum dose and shortest duration principle.

Research evidence / Overview of studies for Optifen Dolo

---

Evidence for use in Acute Pain and Symptom Relief

Research explored the use of the active ingredient in Optifen Dolo for outcomes related to physical discomfort and systemic imbalance, such as general, mild-to-moderate pain and the reduction of fever. The main body of evidence comes from short-term, randomized controlled trials (RCTs) and systematic reviews. These studies measured outcomes such as the intensity of pain and the time until data points related to changes in body temperature were observed.

For acute, general pain, studies reported measurements of short-term differences in pain scores between the tested medicine and comparison groups, such as placebo. For fever, the evidence base includes many comparative trials involving adult and pediatric populations. These trials reported observations showing data points related to changes in body temperature from the starting point. While research offers context regarding short-term changes, evidence is limited regarding the effects of intermittent use over extended periods for either pain or fever management.

Evidence for use in Specific Pain Conditions

Specific trials evaluated the active ingredient in contexts characterized by acute or disruptive episodes like headache, dental pain following minor procedures, and menstrual pain. These were typically double-blind RCTs. In headache research, studies monitored outcomes describing perceived discomfort, particularly the proportion of participants observed to be pain-free at a specific time point, typically two hours post-dose.

For menstrual and post-dental pain, findings describe patterns observed related to changes in pain intensity over defined, short-term intervals. The research for these specific conditions is highly focused on single acute episodes. There is limited information for long-term outcomes, and the trials do not provide insight into any effects of consistent use for chronic conditions.

What is Still Uncertain About the Research for Optifen Dolo

Important gaps in the current research exist. The overall follow-up durations were limited, meaning that long-term effects are not fully established. Data for certain populations remain insufficient, including those with complex comorbidities or very advanced age. Comparative evidence is lacking regarding some other options available. Research provides context but not individual predictions, and studies contribute to the broader evidence landscape rather than offering conclusive, personal outcomes.

Common questions about Optifen Dolo (FAQ)

---

Q: How quickly does Optifen Dolo usually start to work?

Studies on the pharmacokinetics of the active ingredient, ibuprofen, indicate it is rapidly absorbed into the bloodstream. The active substance typically reaches its highest concentration in the blood within 1 to 2 hours after the soft capsule is taken. This timeframe indicates when peak blood concentrations are typically observed, contributing to the onset of the medicine's effect.

---

Q: Is it possible to become dependent on Optifen Dolo?

According to official regulatory classifications, the active ingredient in Optifen Dolo is ibuprofen. Ibuprofen belongs to the class of non-steroidal anti-inflammatory drugs (NSAIDs). Official documents do not classify this medicine as a controlled substance and contain no information suggesting the risk of physical dependence on this medication.

---

Q: Is Optifen Dolo available over-the-counter or does it require a prescription?

Regulatory authorities in many regions approve the standard dose of ibuprofen contained in Optifen Dolo for over-the-counter (OTC) use. This means the medicine is generally available for purchase without the requirement of a prescription. The specific legal classification may vary depending on local pharmaceutical regulations.

---

Q: Does Optifen Dolo cause drowsiness or affect the ability to drive?

Official product documents list potential side effects that affect the central nervous system, such as dizziness and headache. If effects that impair concentration, such as dizziness, are experienced, patients are advised in official materials to use caution when driving or operating machinery.

---

Q: Can people with asthma generally use Optifen Dolo?

Official product information contraindicates the medicine for patients with a known history of severe hypersensitivity reactions to aspirin or other NSAIDs. This is because these reactions can trigger acute asthma attacks (bronchospasm). Due to the potential for severe reactions, official guidance defines that caution is warranted for individuals with pre-existing asthma.

---

Q: Are there any specific foods or drinks that should be avoided when taking Optifen Dolo?

Regulatory labeling consistently advises caution regarding the combined use of Optifen Dolo with alcohol. The combination of NSAIDs and alcohol may increase the documented risk of serious gastrointestinal bleeding. The complete guidance on usage considerations is provided within the official patient information leaflet.

---

Q: What are the general expectations for the duration of Optifen Dolo's effects?

The duration of the medicinal effect is related to the official guidance for repeat administration. Regulatory posology, or dosing rules, typically prescribe a minimum interval of 4 to 6 hours between doses of Optifen Dolo. This interval reflects the medicinal effect and the minimum period of time that must be observed between doses.

---

Q: Is it considered normal to feel a slight burning sensation after taking Optifen Dolo?

Official labeling lists Gastrointestinal Disorders as common side effects, including dyspepsia (indigestion) and abdominal pain. This discomfort may sometimes be perceived as a burning sensation in the stomach. Regulatory documents indicate that any unusual or persistent abdominal symptoms warrant further review.

---

Q: What conditions is Optifen Dolo not indicated for, according to official guidance?

While indicated for short-term relief of pain and fever, the medicine is strictly contraindicated (must not be used) in several specific, severe health conditions. These include active gastrointestinal ulcers, severe organ failures (like heart, liver, or kidney), and in the immediate setting of coronary artery bypass graft (CABG) surgery.

---

Q: Why do some people mistakenly think Optifen Dolo is a narcotic?

The active substance in Optifen Dolo is ibuprofen, which is a synthetic chemical compound classified as a non-steroidal anti-inflammatory drug (NSAID). According to global drug classification schedules, it is not chemically related to opioids and is not classified as a narcotic substance.

---

Q: Is Optifen Dolo gluten-free?

Official product documentation is required to include a full list of all inactive ingredients, or excipients, used in the formulation. The availability of this comprehensive list of components provides information necessary to identify the presence of any potential allergens, including gluten-derived components.

---

Q: What are the non-drug components (excipients) in Optifen Dolo?

Regulatory documents, such as the Summary of Product Characteristics, contain a complete and mandatory list of all non-drug components. These inactive substances are called excipients, and they include all fillers, coatings, and stabilizers used to create the final medicine formulation. This list ensures transparency regarding the complete composition.

Official Storage and Disposal Requirements

Official regulatory documents define specific conditions for storing and disposing of Optifen Dolo to maintain its stability and ensure safety.

Requirement Type	Labeled Instruction
Temperature	Store at room temperature, maintained between 15, C and 25, C.
Protection	Store in the original container to protect the product from humidity (moisture).
Child Safety	Must be kept out of the sight and reach of children.
Stability	Do not use the medicine after the expiration date (EXP) shown on the packaging.
Disposal	Do not dispose of via household waste or wastewater. Discard unused or expired product according to local regulations or return to a pharmacy.

These instructions define that the product must be stored under controlled conditions and strictly prohibit its use past the labeled expiration date. For environmental safety, disposal must adhere to official pharmaceutical waste procedures.